Adipose-Derived Mesenchymal Stem Cells for Treatment Tertiary Failure Diabetes Mellitus Type 2


Article Preview

Recent progress in diabetes mellitus therapy has focused attention on generation of surrogate β-cells from mesenchymal stem cells (MSCs) derived adult tissues. In this study, we conducted a phase I clinical trial in patients with type 2 diabetes mellitus in various age between 30-79 years old who were treated with autologous adipose-derived MSCs transplantation. MSCs injected into diabetic patients through catheterization then we measured levels of fasting blood glucose, 2h postprandial blood glucose, insulin, c-peptide pre and post stem cell transplantation, also HbA1c. Levels of blood glucose (fasting and 2h post prandial) and insulin were absolutely decreasing after injection. Meanwhile, level of c-peptide was increasing after injection. Level of HbA1c was significantly decreasing after 3 months injection. Thus, adipose-derived mesenchymal stem cells for treatment tertiary failure diabetes mellitus type 2 was better than insulin treatment only.





Purwati et al., "Adipose-Derived Mesenchymal Stem Cells for Treatment Tertiary Failure Diabetes Mellitus Type 2", Journal of Biomimetics, Biomaterials and Biomedical Engineering, Vol. 31, pp. 91-95, 2017

Online since:

March 2017




* - Corresponding Author

[1] American Diabetes Association. 2012. Diagnosis and Classification of Diabetes Melitus. Diabetic Care. 35 suppl: 568.

[2] International Diabetes Federation. 2013. IDF Atlas Sixth Edition.

[3] Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. 2007. Laporan Riset Kesehatan Dasar (2007).


[4] Derek Le Roith, Simeon I. Taylor, Jerrold M. Olefsky. 2004. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott William & Wilkins. pp.458-460.

[5] Healthcare Improvement Scotland. 2010. Management of Diabetes: A National Clinical Guideline. Scottish Intercollegiate Guidelines Network. pp.39-54.

[6] R.Y. Calne, S.U. Gan, K.O. Lee. 2010. Stem Cell and Gene Therapies for Diabetes Mellitus, Nat. Rev. Endocrinol. 6 173–177.


[7] Purwati, Fedik. A. R, Sony W, Anas P, Eric H, Helen S, Deya K. 2013. Autologous MSC Bone Marrow Stem Cell and Allogenic Pancreatic Stem Cell for Repair of Beta Pancreatic Cell in Experimental Diabetes Mellitus. African Journal of Internal Medicine, International Scholars Journals Vol. 1 (1), pp.010-016.

[8] Fedik A. Rantam, Purwati, Budi Setiawan, Sony Wibisono, Ferdiansyah, Joni Wahyuhadi, Edward Mouli, Dwikora N. Utomo, Heri Suroto, Candra Bumi. 2015. Induced Monocytes Derived HSCs (CD34+) with LPS Accelerated Homing Rat-Bone Marrow Mesenchymal (CD105) in Injured Pancreas. Journal of Biomedical and Life Sciences Vol. 8 No. 5, pp.333-344.


[9] Taran R, Mamidi MK, Singh G, Dutta S, Parhar IS, John JP, Bhonde R, Pal R, Das AK. 2014. Invitro and Invivo Neurogenic Potensial of Mesenchymal Stem Cell Isolated from Different Sources. Journal of Biosciences 9(1): 157-69.


[10] Trivedi P, Tray N, Nguyen T, Nigam N, Gallicano GI. 2010. Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later. Stem Cells Dev; 19(7): 1109-20.


[11] Diabetes Control and Complications Trial Research Group. 1993. The Effect of Intensive Diabetes Treatment on The Development Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus: The Diabetes Controland Complication Trial. N Engl J Med; 329: 978-986.


[12] De Fronzo RA, Ferrannini E, Keen H, Zimmet P. 2004. International Textbook of Diabetes Mellitus, 3rd Edition. Chichester, UK: John Wiley and Sons.

[13] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. 2006. Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement. Cytotherapy, 8: 315-317.